XLerateHealth Awarded $2.5M NIH Phase IIB Grant to Accelerate National Expansion of Its Enterprise Commercialization Engine

XLerateHealth received a $2.5 million NIH/NIGMS Phase IIB grant to scale its Commercialization Engine for universities, biotech hubs, health systems and entrepreneurial support organizations. The funding supports expansion of biotechnology commercialization infrastructure, but is unlikely to have broad public-market implications.